Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: A promising strategy ready for clinical testing

Annals of Oncology

Volumn 13, Issue 1, 2002, Pages 8-9

  Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; TRASTUZUMAB;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; ONCOGENE NEU; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL TRANSDUCTION; TREATMENT PLANNING; TUMOR CLASSIFICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 0036224486     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdf092     Document Type: Editorial

References (17)

1. Untangling the ErbB signalling network
2. Epidermal growth factor-related peptides and their receptors in human malignancies
3. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neuoncogene
4. Epidermal growth factor receptor: A marker of early relapse in breast cancer and tumor stage progression in bladder cancer; interactions with neu
5. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
6. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast disease
7. Efficacy and safety of herceptin (trastuzumab humanized anti-HER2 antibody) as a single agent in first-line treatment of HER2 overexpressing metastatic breast cancer (HER2+/MBC)
8. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
9. Targeting the epidermal growth factor receptor: A clinical reality
10. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
11. Continued response following treatment with IMC-C225, an EGFr MoAb, combined with RT in advanced head and neck carcinoma
12. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
13. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
14. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
15. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
16. Small molecule EGF receptor tyrosine kinase inhibitor ZD1839 (IRESSA) inhibits HER2/Neu (erb-2) overexpressing breast tumor cells
17. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells